Actuate Therapeutics (ACTU) said Friday that its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer demonstrated the use of machine learning and statistical models to predict overall survival based on pre-dose plasma biomarkers.
The analysis identified seven biomarkers as "uniquely significant" predictors of favorable survival in the elraglusib-treated cohort, the biopharmaceutical company said.
The biomarker CXCL2 had an inverse survival trend compared to the gemcitabine/nab-paclitaxel control arm, "highlighting the potential of elraglusib to favorably affect the immune microenvironment," Actuate said.
The company said it plans to test the identified biomarkers prospectively in future trials.
Shares were 5.8% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.